431 related articles for article (PubMed ID: 31697823)
1. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
Li B; Brady SW; Ma X; Shen S; Zhang Y; Li Y; Szlachta K; Dong L; Liu Y; Yang F; Wang N; Flasch DA; Myers MA; Mulder HL; Ding L; Liu Y; Tian L; Hagiwara K; Xu K; Zhou X; Sioson E; Wang T; Yang L; Zhao J; Zhang H; Shao Y; Sun H; Sun L; Cai J; Sun HY; Lin TN; Du L; Li H; Rusch M; Edmonson MN; Easton J; Zhu X; Zhang J; Cheng C; Raphael BJ; Tang J; Downing JR; Alexandrov LB; Zhou BS; Pui CH; Yang JJ; Zhang J
Blood; 2020 Jan; 135(1):41-55. PubMed ID: 31697823
[TBL] [Abstract][Full Text] [Related]
2. Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia.
Barz MJ; Hof J; Groeneveld-Krentz S; Loh JW; Szymansky A; Astrahantseff K; von Stackelberg A; Khiabanian H; Ferrando AA; Eckert C; Kirschner-Schwabe R
Blood; 2020 Mar; 135(12):921-933. PubMed ID: 31971569
[TBL] [Abstract][Full Text] [Related]
3. FPGS relapse-specific mutations in relapsed childhood acute lymphoblastic leukemia.
Yu SL; Zhang H; Ho BC; Yu CH; Chang CC; Hsu YC; Ni YL; Lin KH; Jou ST; Lu MY; Chen SH; Wu KH; Wang SC; Chang HH; Pui CH; Yang JJ; Zhang J; Lin DT; Lin SW; Ma X; Yang YL
Sci Rep; 2020 Jul; 10(1):12074. PubMed ID: 32694622
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-Mediated Induction of Relapse-Specific
Nguyen TTT; Tanaka Y; Sanada M; Hosaka M; Tamai M; Kagami K; Komatsu C; Somazu S; Harama D; Kasai S; Watanabe A; Akahane K; Goi K; Inukai T
Mol Pharmacol; 2023 Apr; 103(4):199-210. PubMed ID: 36669880
[TBL] [Abstract][Full Text] [Related]
5. Unravelling the Sequential Interplay of Mutational Mechanisms during Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia.
Antić Ž; Lelieveld SH; van der Ham CG; Sonneveld E; Hoogerbrugge PM; Kuiper RP
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33540666
[TBL] [Abstract][Full Text] [Related]
6. Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.
Dieck CL; Tzoneva G; Forouhar F; Carpenter Z; Ambesi-Impiombato A; Sánchez-Martín M; Kirschner-Schwabe R; Lew S; Seetharaman J; Tong L; Ferrando AA
Cancer Cell; 2018 Jul; 34(1):136-147.e6. PubMed ID: 29990496
[TBL] [Abstract][Full Text] [Related]
7. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.
Meyer JA; Wang J; Hogan LE; Yang JJ; Dandekar S; Patel JP; Tang Z; Zumbo P; Li S; Zavadil J; Levine RL; Cardozo T; Hunger SP; Raetz EA; Evans WE; Morrison DJ; Mason CE; Carroll WL
Nat Genet; 2013 Mar; 45(3):290-4. PubMed ID: 23377183
[TBL] [Abstract][Full Text] [Related]
8. NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia.
Tulstrup M; Grosjean M; Nielsen SN; Grell K; Wolthers BO; Wegener PS; Jonsson OG; Lund B; Harila-Saari A; Abrahamsson J; Vaitkeviciene G; Pruunsild K; Toft N; Holm M; Hulegårdh E; Liestøl S; Griskevicius L; Punab M; Wang J; Carroll WL; Zhang Z; Dalgaard MD; Gupta R; Nersting J; Schmiegelow K
Leukemia; 2018 Dec; 32(12):2527-2535. PubMed ID: 30201983
[TBL] [Abstract][Full Text] [Related]
9. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
Tzoneva G; Perez-Garcia A; Carpenter Z; Khiabanian H; Tosello V; Allegretta M; Paietta E; Racevskis J; Rowe JM; Tallman MS; Paganin M; Basso G; Hof J; Kirschner-Schwabe R; Palomero T; Rabadan R; Ferrando A
Nat Med; 2013 Mar; 19(3):368-71. PubMed ID: 23377281
[TBL] [Abstract][Full Text] [Related]
10. NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells.
Somazu S; Tanaka Y; Tamai M; Watanabe A; Kagami K; Abe M; Harama D; Shinohara T; Akahane K; Goi K; Sugita K; Moriyama T; Yang J; Goto H; Minegishi M; Iwamoto S; Takita J; Inukai T
J Cell Mol Med; 2021 Nov; 25(22):10521-10533. PubMed ID: 34636169
[TBL] [Abstract][Full Text] [Related]
11. Screening for gene mutations: will identification of NT5C2 mutations help predict the chance of relapse in acute lymphoblastic leukemia?
Meyer JA; Carroll WL; Bhatla T
Expert Rev Hematol; 2013 Jun; 6(3):223-4. PubMed ID: 23782074
[No Abstract] [Full Text] [Related]
12. Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets.
Hoell JI; Ginzel S; Kuhlen M; Kloetgen A; Gombert M; Fischer U; Hein D; Demir S; Stanulla M; Schrappe M; Zur Stadt U; Bader P; Babor F; Schuster F; Strahm B; Alten J; Moericke A; Escherich G; von Stackelberg A; Thiele R; McHardy AC; Peters C; Bornhauser B; Bourquin JP; Krause S; Enczmann J; Meyer LH; Eckert C; Borkhardt A; Meisel R
Blood Adv; 2019 Oct; 3(20):3143-3156. PubMed ID: 31648313
[TBL] [Abstract][Full Text] [Related]
13. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.
Ma X; Edmonson M; Yergeau D; Muzny DM; Hampton OA; Rusch M; Song G; Easton J; Harvey RC; Wheeler DA; Ma J; Doddapaneni H; Vadodaria B; Wu G; Nagahawatte P; Carroll WL; Chen IM; Gastier-Foster JM; Relling MV; Smith MA; Devidas M; Guidry Auvil JM; Downing JR; Loh ML; Willman CL; Gerhard DS; Mullighan CG; Hunger SP; Zhang J
Nat Commun; 2015 Mar; 6():6604. PubMed ID: 25790293
[TBL] [Abstract][Full Text] [Related]
14. Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia.
Lu SX; Abdel-Wahab O
Proc Natl Acad Sci U S A; 2016 Oct; 113(40):11071-11073. PubMed ID: 27663730
[No Abstract] [Full Text] [Related]
15. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
Tzoneva G; Dieck CL; Oshima K; Ambesi-Impiombato A; Sánchez-Martín M; Madubata CJ; Khiabanian H; Yu J; Waanders E; Iacobucci I; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Gastier-Foster JM; Loh ML; Kirschner-Schwabe R; Mullighan CG; Rabadan R; Ferrando AA
Nature; 2018 Jan; 553(7689):511-514. PubMed ID: 29342136
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of monitoring peripheral blood to detect emerging clones in children with acute lymphoblastic leukemia
Saliba J; Evensen NA; Meyer JA; Newman D; Nersting J; Narang S; Ma X; Schmiegelow K; Carroll WL
Pediatr Blood Cancer; 2020 Jul; 67(7):e28306. PubMed ID: 32391957
[TBL] [Abstract][Full Text] [Related]
17. Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation.
Kunz JB; Rausch T; Bandapalli OR; Eilers J; Pechanska P; Schuessele S; Assenov Y; Stütz AM; Kirschner-Schwabe R; Hof J; Eckert C; von Stackelberg A; Schrappe M; Stanulla M; Koehler R; Avigad S; Elitzur S; Handgretinger R; Benes V; Weischenfeldt J; Korbel JO; Muckenthaler MU; Kulozik AE
Haematologica; 2015 Nov; 100(11):1442-50. PubMed ID: 26294725
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse.
Yang F; Brady SW; Tang C; Sun H; Du L; Barz MJ; Ma X; Chen Y; Fang H; Li X; Kolekar P; Pathak O; Cai J; Ding L; Wang T; von Stackelberg A; Shen S; Eckert C; Klco JM; Chen H; Duan C; Liu Y; Li H; Li B; Kirschner-Schwabe R; Zhang J; Zhou BS
Nat Cancer; 2021 Aug; 2(8):819-834. PubMed ID: 35122027
[TBL] [Abstract][Full Text] [Related]
19. Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse.
Antić Ž; Yu J; Bornhauser BC; Lelieveld SH; van der Ham CG; van Reijmersdal SV; Morgado L; Elitzur S; Bourquin JP; Cazzaniga G; Eckert C; Camós M; Sutton R; Cavé H; Moorman AV; Sonneveld E; Geurts van Kessel A; van Leeuwen FN; Hoogerbrugge PM; Waanders E; Kuiper RP
Pediatr Blood Cancer; 2022 Jan; 69(1):e29361. PubMed ID: 34597466
[TBL] [Abstract][Full Text] [Related]
20. Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.
Dieck CL; Ferrando A
Blood; 2019 May; 133(21):2263-2268. PubMed ID: 30910786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
